文献速递复苏、休克与脓毒症

基于营养状态的模型预测低乳酸休克:一项回顾性队列研究

Nutritional Status-Based Model for Predicting Low-Lactate Shock: A Retrospective Cohort Study.
PubMed 文献 · Shock · 2025-09-23
一句话结论低乳酸休克患者28天死亡率达25.4%,NRS-APACHE II-TG-TBIL模型(AUC=0.800)可用于早期识别。

该回顾性队列研究纳入2015年1月至2022年3月一家三级医疗机构的3134例休克患者,采用1:2倾向性评分匹配控制混杂因素,旨在确定低乳酸休克(乳酸≤2.0 mmol/L)的患病率、危险因素并验证预测模型。低乳酸休克组28天死亡率为25.4%(94/369),较高乳酸组的35.8%(990/2765)略低。多变量分析识别出NRS-2002、APACHE II、甘油三酯和总胆红素四个独立预测因素,构建的NRS-APACHE II-TG-TBIL模型AUC为0.800,敏感性72.6%,特异性73.5%。该模型为早期识别低乳酸休克提供了有效工具,弥补了当前休克管理中的诊断缺口。

要点

  • 低乳酸休克(乳酸≤2.0 mmol/L)患者28天死亡率为25.4%(94/369),较高乳酸组的35.8%(990/2765)略低。
  • NRS-2002(OR=0.570,P<0.001)、APACHE II(OR=0.869,P<0.001)、甘油三酯(OR=0.772,P=0.035)和总胆红素(OR=0.993,P=0.002)是低乳酸休克的独立预测因素。
  • NRS-APACHE II-TG-TBIL模型区分度良好(AUC=0.800,P<0.001),敏感性72.6%,特异性73.5%。
  • 低乳酸休克组的年龄、NRS-2002评分和静脉血栓栓塞风险评分显著低于高乳酸休克组(P<0.05),性别分布无统计学显著差异(P=0.092)。

适用人群与场景

  • 2015年1月至2022年3月一家三级医疗机构收治的3134例休克患者。

诊断标准与关键阈值

  • 低乳酸休克定义为乳酸≤2.0 mmol/L。
  • Sepsis-3.0定义脓毒性休克为低血压伴血清乳酸>2.0 mmol/L,该标准可能遗漏低乳酸休克。

研究设计与关键结果

  • 研究类型为回顾性队列研究,样本量3134例,单家三级医疗机构,采用1:2倾向性评分匹配控制混杂因素。
  • 低乳酸休克组28天死亡率为25.4%(94/369),高乳酸组为35.8%(990/2765)。
  • 低乳酸休克组年龄、NRS-2002评分和静脉血栓栓塞风险评分显著低于高乳酸休克组(P<0.05),性别分布无统计学显著差异(P=0.092)。
  • 多变量分析显示NRS-2002(OR=0.570,P<0.001)、APACHE II(OR=0.869,P<0.001)、甘油三酯(OR=0.772,P=0.035)和总胆红素(OR=0.993,P=0.002)为低乳酸休克的独立预测因素。
  • NRS-APACHE II-TG-TBIL模型AUC=0.800(P<0.001),敏感性72.6%,特异性73.5%。

证据类型、等级与局限

  • 证据类型:回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为NRS-APACHE II-TG-TBIL模型(AUC=0.800)为早期发现低乳酸休克提供了有效工具,弥补了休克管理中的关键诊断缺口。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Although Sepsis-3.0 defines septic shock as hypotension with serum lactate levels >2.0 mmol/L, this criterion may miss low-lactate shock: a clinically significant phenotype characterized by hypotension but without elevated lactate levels. The epidemiological characteristics and prognostic significance of low-lactate shock remain unclear, highlighting a critical gap in current shock management models.

METHODS: We conducted a retrospective cohort study of 3,134 patients with shock admitted to a tertiary care medical institution from January 2015 to March 2022. We used propensity score matching (1:2 ratio) to control for confounding factors, aiming to determine the prevalence of low-lactate shock (lactate ≤ 2.0 mmol/L), identify risk factors through multivariable logistic regression, and validate the predictive model [Nutritional Risk Screening-2002-Acute Physiology and Chronic Health Evaluation-Triglycerides-Total Bilirubin (NRS-APACHE II-TG-TBIL)] using receiver operating characteristic analysis.

RESULTS: The 28-day mortality rate was slightly lower in the low-lactate shock group compared with the high-lactate group [25.4% (94/369) vs. 35.8% (990/2,765), respectively]. The age, Nutritional Risk Screening-2002 (NRS-2002) score, and venous thromboembolism risk score were significantly lower in the low-lactate shock group than in the high-lactate shock group ( P < 0.05). No statistically significant differences were observed in gender distribution ( P = 0.092). Multivariable analysis identified four independent predictors of low-lactate shock: NRS-2002 [odds ratio (OR) = 0.570, P < 0.001], Acute Physiology and Chronic Health Evaluation II (APACHE II) (OR = 0.869, P < 0.001), triglycerides (OR = 0.772, P = 0.035), and total bilirubin (OR = 0.993, P = 0.002). The composite NRS-APACHE II-TG-TBIL model showed excellent discrimination (area under curve = 0.800, P < 0.001) with balanced sensitivity (72.6%) and specificity (73.5%).

CONCLUSIONS: Low-lactate shock carries substantial mortality risk (25.4%). The validated NRS-APACHE II-TG-TBIL model (area under curve = 0.800) provides an effective tool for early detection, addressing critical diagnostic gaps in shock management.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Xu X, Hu F, Zhang Z, et al. Nutritional Status-Based Model for Predicting Low-Lactate Shock: A Retrospective Cohort Study. Shock. 2025. PMID: 40986916. doi:10.1097/SHK.0000000000002710

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。